Regeneron: Is The Market Undervaluing Its Growth Potential (NASDAQ:REGN)
· seekingalpha.com
Regeneron Pharmaceuticals, Inc. Q3 earnings preview: click for how Dupixent growth, positive Phase 3 results, and a discounted valuation support REGN risk/reward.
Following my August article , "Regeneron: Why I Still See Upside After The Rally," which focused primarily on the anti-PD-1 mAb Opdivo and the blockbuster, call...